See today's BioWorld Asia
To read the full story, subscribe or sign in.

Cansino steps closer to COVID-19 mRNA vaccine approval in China

May 30, 2023
By Doris Yu
Cansino Biologics Inc. reported positive data in a phase IIb trial evaluating the heterologous mRNA vaccine CS-2034 booster compared to an inactivated vaccine to prevent SARS-CoV-2 infections.
BioWorld Asia Clinical Coronavirus Vaccine China